Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | PPME1 | Q9Y570 | 2/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | PARL | Q9H300 | 1/20 | 0.33 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5149713 | 0.82 | MEN1 (0.43) | MEN1KMT2ACA1CA2CA9 | |
| SCHEMBL5156340 | 0.80 | KMT2A (0.43) | MEN1KMT2A | |
| SCHEMBL5156384 | 0.79 | KMT2A (0.41) | HTR6MEN1KMT2ACA1CA2 | |
| SCHEMBL7161021 | 0.66 | CACNA1B (0.45) | MEN1KMT2ACACNA1B | |
| SCHEMBL5155519 | 0.62 | HCRTR1 (0.49) | MEN1KMT2APTGS1PTGS2CACNA1B | |
| SCHEMBL4830073 | 0.62 | HTR6 (0.46) | HTR6MEN1KMT2APPME1 | |
| SCHEMBL8444032 | 0.59 | PTGS1 (0.65) | MEN1KMT2APTGS1PTGS2 | |
| SCHEMBL29699041 | 0.58 | HTR6 (0.42) | HTR6 | |
| SCHEMBL1616366 | 0.57 | PPME1 (0.60) | HTR6MEN1KMT2APPME1 | |
| SCHEMBL14760380 | 0.57 | HTR6 (0.50) | HTR6MEN1KMT2APPME1MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7223754-B2 | Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders | DYNOGEN PHARMACEUTICALS, INC. (US) | 2007-05-29 | — | — | US | disclosed |
| US-20070066597-A1 | Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders | DYNOGEN PHARMACEUTICALS, INC. (US) | 2007-03-22 | — | — | US | disclosed |
| US-20050148587-A1 | Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders | DYNOGEN PHARMACEUTICALS, INC. (US) | 2005-07-07 | — | — | US | disclosed |
| US-20050113421-A1 | Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating non-inflammatory gastrointestinal tract disorders | DYNOGEN PHARMACEUTICALS, INC. (US) | 2005-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113421-A1 | Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating non-inflammatory gastrointestinal tract disorders | TRPV2, RYR2, VDAC2 | HTR6 1595/4885MEN1 3532/4885KMT2A 4084/4885 |
| US-20070066597-A1 | Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders | RYR2, CACNB2, CACNA1I | HTR6 2280/4885MEN1 3820/4885KMT2A 3401/4885 |
| US-20050148587-A1 | Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders | RYR2, CACNB2, CACNA1I | HTR6 2280/4885MEN1 3820/4885KMT2A 3401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.